A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Summary

To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.

Timeline

Start

2023-03-06

Primary completion

2029-11-22

Completion

2029-11-22

Publications

• Soo RA, de Marinis F, Han JY, Ho JC, Martin E, Servidio L, Sandelin M, Popat S. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection. Clin Lung Cancer. 2024 Jan;25(1):80-84. doi: 10.1016/j.cllc.2023.09.005. Epub 2023 Oct 4.

Drugs

Indications